Studies report that a reduced renal function represents a higher risk of developing cardiotoxicity at 12-month follow-up in patients with HER-2-positive early breast cancer treated with anti-Her-2 target therapy [15, 22]. This evidence concerns the gene ERBB2 and breast carcinoma.